Prospective study of sickle cell trait and venous thromboembolism incidence

Journal of Thrombosis and Haemostasis

Volumn 13, Issue 1, 2015, Pages 2-9

  Folsom, Aaron R ^a   Tang, W ^a   Roetker, N S ^a   Kshirsagar, A V ^b   Derebail, V K ^b   Lutsey, P L ^a   Naik, R ^c   Pankow, J S ^a   Grove, M L ^d   Basu, S ^a   Key, N S ^b   Cushman, M ^e  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Epidemiology; Prospective study; Risk factors; Sickle cell trait; Venous thromboembolism

Indexed keywords

HEMOGLOBIN S;

ADULT; AFRICAN AMERICAN; ARTICLE; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GENOTYPE; GLOMERULUS FILTRATION RATE; HORMONE SUBSTITUTION; HUMAN; INCIDENCE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; PRIORITY JOURNAL; PROSPECTIVE STUDY; SICKLE CELL TRAIT; CLINICAL TRIAL; EPIDEMIOLOGY; ETHNOLOGY; GENETICS; MULTICENTER STUDY; PULMONARY EMBOLISM; RISK ASSESSMENT; RISK FACTOR; TIME FACTOR; UNITED STATES; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

AFRICAN AMERICANS; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PULMONARY EMBOLISM; RISK ASSESSMENT; RISK FACTORS; SICKLE CELL TRAIT; TIME FACTORS; UNITED STATES; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 84921029760     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12787     Document Type: Article

References (30)

1. Naik RP, Streiff MB, Haywood C Jr, Nelson JA, Lanzkron S. Venous thromboembolism in adults with sickle cell disease: a serious and under-recognized complication. Am J Med 2013; 126: 443-9.
2. Stein PD, Beemath A, Meyers FA, Skaf E, Olson RE. Deep venous thrombosis and pulmonary embolism in hospitalized patients with sickle cell disease. Am J Med 2006; 119: 897.e7-11.
3. Porter B, Key NS, Jauk VC, Adam S, Biggio J, Tita A. Impact of sickle hemoglobinopathies on pregnancy-related venous thromboembolism. Am J Perinatol 2014; 31: 805-10.
4. Lim MY, Ataga KI, Key NS. Hemostatic abnormalities in sickle cell disease. Curr Opin Hematol 2013; 20: 472-7.
5. Ataga KI, Key NS. Hypercoagulability in sickle cell disease: new approaches to an old problem. Hematology Am Soc Hematol Educ Program 2007; 1: 91-6.
6. Westerman MP, Green D, Gilman-Sachs A, Beaman K, Freels S, Boggio L, Allen S, Schlegel R, Williamson P. Coagulation changes in individuals with sickle cell trait. Am J Hematol 2002; 69: 89-94.
7. Austin H, Key NS, Benson JM, Lally C, Dowling NF, Whitsett C, Hooper WC. Sickle cell trait and the risk of venous thromboembolism among blacks. Blood 2007; 110: 908-12.
8. Bucknor MD, Goo JS, Coppolino ML. The risk of potential thromboembolic, renal and cardiac complications of sickle cell trait. Hemoglobin 2014; 38: 28-32.
9. Heller P, Best WR, Nelson RB, Becktel J. Clinical implications of sickle-cell trait and glucose-6-phosphate dehydrogenase deficiency in hospitalized black male patients. N Engl J Med 1979; 300: 1001-5.
10. The ARIC Investigators. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. Am J Epidemiol 1989; 129: 687-702.
11. Cushman M, Tsai AW, White RH, Heckbert SR, Rosamond WD, Enright P, Folsom AR. Deep vein thrombosis and pulmonary embolism in two cohorts: the Longitudinal Investigation of Thromboembolism Etiology. Am J Med 2004; 117: 19-25.
12. Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Polak JF, Folsom AR. Cardiovascular risk factors and venous thromboembolism incidence: the Longitudinal Investigation of Thromboembolism Etiology. Arch Intern Med 2002; 162: 1182-9.
13. Reid JG, Carroll A, Veeraraghavan N, Dahdouli M, Sundquist A, English A, Bainbridge M, White S, Salerno W, Buhay C, Yu F, Muzny D, Daly R, Duyk G, Gibbs RA, Boerwinkle E. Launching genomics into the cloud: deployment of Mercury, a next generation sequence analysis. BMC Bioinformatics 2014; 15: 30.
14. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, Manzi J, van Lente F, Zhang YL, Coresh J, Levey AS, for the CKD-EPI Investigators. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 2012; 367: 20-9.
15. Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Tracy RP, Aleksic N, Folsom AR. Coagulation factors, inflammation markers, and venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology (LITE). Am J Med 2002; 113: 636-42.
16. Zakai NA, Ohira T, White R, Folsom AR, Cushman M. Activated partial thromboplastin time and risk of future venous thromboembolism. Am J Med 2008; 121: 231-8.
17. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006; 38: 904-9.
18. Embury SH, Clark MR, Monroy G, Mohandas N. Concurrent sickle cell anemia and alpha-thalassemia. Effect on pathological properties of sickle erythrocytes. J Clin Invest 1984; 73: 116-23.
19. Gupta AK, Kirchner KA, Nicholson R, Adams JG III, Schechter AN, Noguchi CT, Steinberg MH. Effects of alpha-thalassemia and sickle polymerization tendency on the urine-concentrating defect of individuals with sickle cell trait. J Clin Invest 1991; 88: 1963-8.
20. Martinelli I, Battaglioli T, Razzari C, Mannucci PM. Type and location of venous thromboembolism in patients with factor V Leiden or prothrombin G20210A and in those with no thrombophilia. J Thromb Haemost 2007; 5: 98-101.
21. van Langevelde K, Srámek A, Vincken PW, van Rooden JK, Rosendaal FR, Cannegieter SC. Finding the origin of pulmonary emboli with a total-body magnetic resonance direct thrombus imaging technique. Haematologica 2013; 98: 309-15.
22. van Langevelde K, Flinterman LE, van Hylckama Vileg A, Rosendaal FR, Cannegieter SC. Broadening the factor V Leiden paradox: pulmonary embolism and deep-vein thrombosis as 2 sides of the spectrum. Blood 2012; 120: 933-46.
23. Hamer JD, Malone PC, Silver IA. The PO2 in venous valve pockets: its possible bearing on thrombogenesis. Br J Surg 1981; 68: 166-70.
24. Whelihan MF, Mooberry MJ, Zachary V, Bradford RL, Ataga KI, Mann KG, Key NS. The contribution of red blood cells to thrombin generation in sickle cell disease: meizothrombin generation on sickled red blood cells. J Thromb Haemost 2013; 11: 2187-9.
25. Mekontso Dessap A, Deux JF, Abidi N, Lavenu-Bombled C, Melica G, Renaud B, Godeau B, Adnot S, Brochard L, Brun-Buisson C, Galacteros F, Rahmouni A, Habbi A, Maitre B. Pulmonary artery thrombosis during acute chest syndrome in sickle cell disease. Am J Respir Crit Care Med 2011; 184: 1022-9.
26. Adedeji MO, Cespedes J, Allen K, Subramony C, Hughson MD. Pulmonary thrombotic arteriopathy in patients with sickle cell disease. Arch Pathol Lab Med 2001; 125: 1436-41.
27. Naik RP, Streiff MB, Lanzkron S. Sickle cell disease and venous thromboembolism: what the anticoagulation expert needs to know. J Thromb Thrombolysis 2013; 35: 352-8.
28. White RH, Dager WE, Zhou H, Murin S. Racial and gender differences in the incidence of recurrent venous thromboembolism. Thromb Haemost 2006; 96: 267-73.
29. Stein PD, Kayali F, Olson RE, Milford CE. Pulmonary thromboembolism in American Indians and Alaskan natives. Arch Intern Med 2004; 164: 1804-6.
30. Sode BF, Allin KH, Dahl M, Gyntelberg F, Nordestgaard BG. Risk of venous thromboembolism and myocardial infarction associated with factor V Leiden and prothrombin mutations and blood type. CMAJ 2013; 185: E229-37.